SGCG and COVID-19: To further evaluate the functionality of type I and II IFN signaling in the context of our finding of reduced baseline whole protein expression of STAT1, we stimulated PBMCs of healthy controls, mildly and severely affected COVID‐19 patients with low doses of either IFN‐α or IFN‐γ for 48 h.